Gemcitabin helye a lokálisan elo{double acute}rehaladott vagy metasztatikus húgyhólyagrák kezelésében

Research output: Contribution to journalArticle

Abstract

M-VAC combination chemotherapy was considered as the "gold standard" of the treatment of advanced and metastatic bladder cancers. Arrival of gemcitabine or taxanes in the 90s attracted attention since their efficacy was combined with low toxicity profiles. Gemcitabine/cisplatin combination became the most frequently studied treatment modality in the past 3 years. Multicentric, multinational randomized phase-III study indicated that in bladder cancer the gemcitabine/cisplatin combination is equal to M-VAC while in the case of the former the risk to benefit ratio is lower. Accordingly, gemcitabine/cisplatin combination is a safer treatment option in advanced and metastatic bladder cancer and is a real alternative to M-VAC. In the case of patients where cisplatin cannot be administered due to poor renal function, the new drugs with better toxicity profiles provide further treatment options.

Original languageHungarian
Pages (from-to)198-203
Number of pages6
JournalMagyar Onkologia
Volume47
Issue number2
Publication statusPublished - 2003

ASJC Scopus subject areas

  • Oncology

Cite this

Gemcitabin helye a lokálisan elo{double acute}rehaladott vagy metasztatikus húgyhólyagrák kezelésében. / Bodrogi, I.

In: Magyar Onkologia, Vol. 47, No. 2, 2003, p. 198-203.

Research output: Contribution to journalArticle

@article{9b7e30e9a49f4375b8d8c3335162ba1b,
title = "Gemcitabin helye a lok{\'a}lisan elo{double acute}rehaladott vagy metasztatikus h{\'u}gyh{\'o}lyagr{\'a}k kezel{\'e}s{\'e}ben",
abstract = "M-VAC combination chemotherapy was considered as the {"}gold standard{"} of the treatment of advanced and metastatic bladder cancers. Arrival of gemcitabine or taxanes in the 90s attracted attention since their efficacy was combined with low toxicity profiles. Gemcitabine/cisplatin combination became the most frequently studied treatment modality in the past 3 years. Multicentric, multinational randomized phase-III study indicated that in bladder cancer the gemcitabine/cisplatin combination is equal to M-VAC while in the case of the former the risk to benefit ratio is lower. Accordingly, gemcitabine/cisplatin combination is a safer treatment option in advanced and metastatic bladder cancer and is a real alternative to M-VAC. In the case of patients where cisplatin cannot be administered due to poor renal function, the new drugs with better toxicity profiles provide further treatment options.",
author = "I. Bodrogi",
year = "2003",
language = "Hungarian",
volume = "47",
pages = "198--203",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Gemcitabin helye a lokálisan elo{double acute}rehaladott vagy metasztatikus húgyhólyagrák kezelésében

AU - Bodrogi, I.

PY - 2003

Y1 - 2003

N2 - M-VAC combination chemotherapy was considered as the "gold standard" of the treatment of advanced and metastatic bladder cancers. Arrival of gemcitabine or taxanes in the 90s attracted attention since their efficacy was combined with low toxicity profiles. Gemcitabine/cisplatin combination became the most frequently studied treatment modality in the past 3 years. Multicentric, multinational randomized phase-III study indicated that in bladder cancer the gemcitabine/cisplatin combination is equal to M-VAC while in the case of the former the risk to benefit ratio is lower. Accordingly, gemcitabine/cisplatin combination is a safer treatment option in advanced and metastatic bladder cancer and is a real alternative to M-VAC. In the case of patients where cisplatin cannot be administered due to poor renal function, the new drugs with better toxicity profiles provide further treatment options.

AB - M-VAC combination chemotherapy was considered as the "gold standard" of the treatment of advanced and metastatic bladder cancers. Arrival of gemcitabine or taxanes in the 90s attracted attention since their efficacy was combined with low toxicity profiles. Gemcitabine/cisplatin combination became the most frequently studied treatment modality in the past 3 years. Multicentric, multinational randomized phase-III study indicated that in bladder cancer the gemcitabine/cisplatin combination is equal to M-VAC while in the case of the former the risk to benefit ratio is lower. Accordingly, gemcitabine/cisplatin combination is a safer treatment option in advanced and metastatic bladder cancer and is a real alternative to M-VAC. In the case of patients where cisplatin cannot be administered due to poor renal function, the new drugs with better toxicity profiles provide further treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84874952433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874952433&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 198

EP - 203

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -